Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M123,383Revenue $M20,063Net Margin (%)25.7Z-Score2.7
Enterprise Value $M127,072EPS $6.7Operating Margin %30.9F-Score5
P/E(ttm))24.3Cash Flow Per Share $6.7Pre-tax Margin (%)27.8Higher ROA y-yN
Price/Book4.810-y EBITDA Growth Rate %11.4Quick Ratio4.6Cash flow > EarningsY
Price/Sales6.25-y EBITDA Growth Rate %10.6Current Ratio5.0Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %15.6ROA % (ttm)7.5Higher Current Ratio y-yY
Dividend Yield %1.6Insider Buy (3m)1ROE % (ttm)21.4Less Shares Outstanding y-yN
Payout Ratio %36.0Shares Outstanding M759ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNDaniel Loeb 2014-12-31 Add13.4%$130.45 - $171.64
($155.84)
$ 162.594%Add 705.66%10,675,000
AMGNVanguard Health Care Fund 2014-12-31 Reduce-0.51%$130.45 - $171.64
($155.84)
$ 162.594%Reduce -20.54%5,580,485
AMGNMario Gabelli 2014-12-31 Reduce-0.02%$130.45 - $171.64
($155.84)
$ 162.594%Reduce -34.11%39,500
AMGNJoel Greenblatt 2014-12-31 Add0.01%$130.45 - $171.64
($156.25)
$ 162.594%Add 285.93%10,393
AMGNDaniel Loeb 2014-09-30 Add1.39%$115.39 - $144.01
($130.57)
$ 162.5920%Add 194.44%1,325,000
AMGNVanguard Health Care Fund 2014-09-30 Reduce-0.32%$115.39 - $144.01
($130.57)
$ 162.5920%Reduce -12.75%7,022,755
AMGNJean-Marie Eveillard 2014-09-30 Buy 0.25%$115.39 - $144.01
($130.57)
$ 162.5920%New holding714,178
AMGNJohn Hussman 2014-09-30 Reduce-0.23%$115.39 - $144.01
($130.57)
$ 162.5920%Reduce -50.00%25,000
AMGNKen Fisher 2014-09-30 Add0.02%$115.39 - $144.01
($130.57)
$ 162.5920%Add 83.59%156,629
AMGNJoel Greenblatt 2014-09-30 Reduce-0.01%$115.39 - $144.01
($130.57)
$ 162.5920%Reduce -72.90%2,693
AMGNJohn Hussman 2014-06-30 Reduce-0.93%$110.29 - $126.07
($115.72)
$ 162.5929%Reduce -66.67%50,000
AMGNDaniel Loeb 2014-06-30 Buy 0.65%$110.29 - $126.07
($115.72)
$ 162.5929%New holding450,000
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 162.5929%New holding9,938
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 162.5929%Add 85.28%60,335
AMGNKen Fisher 2014-06-30 Add0.01%$110.29 - $126.07
($115.72)
$ 162.5929%Add 71.02%85,316
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 162.5926%Reduce -9.42%32,161,744
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 162.5926%Reduce -6.40%8,213,855
AMGNJohn Hussman 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 162.5926%Reduce -14.29%150,000
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 162.5926%Sold Out0
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 162.5926%Add 37.87%32,565
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Tross Stuart ASVP, Human Resources 2015-03-03Sell4,415$157.741.78view
BALTIMORE DAVIDDirector 2015-03-02Sell3,647$158.761.13view
Bradway Robert AChairman, CEO and President 2015-02-11Sell22,000$152.695.15view
HERRINGER FRANK CDirector 2015-02-05Buy3,000$152.295.42view
de Carbonnel FrancoisDirector 2014-12-03Sell3,000$168.01-4.44view
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2926.13view
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9725.46view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8342.29view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7743.64view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4545.36view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
    Third Point LLC: Fourth Quarter Letter To Investors Feb 13 2015 
    Daniel Loeb Comments on Amgen Inc Feb 10 2015 
    Dan Loeb Fourth Quarter Investor Letter Feb 10 2015 
    Daniel Loeb’s Third Point Q4 2014 Investor Letter Feb 09 2015 
    New Guru Jana Partners' Newest Stock Buys Jan 23 2015 
    Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy Jan 07 2015 
    Druckenmiller Adds Healthcare Stocks to Portfolio Dec 15 2014 
    Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pa Dec 02 2014 
    Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 


    More From Other Websites
    Final Glance: Biotechnology companies Mar 26 2015
    Final Glance: Biotechnology companies Mar 26 2015
    Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins... Mar 26 2015
    Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins... Mar 26 2015
    Midday Glance: Biotechnology companies Mar 26 2015
    Midday Glance: Biotechnology companies Mar 26 2015
    Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks Mar 26 2015
    Healthcare Hedge Fund Orbimed’s Top Picks and New Move Mar 26 2015
    Early Glance: Biotechnology companies Mar 26 2015
    Early Glance: Biotechnology companies Mar 26 2015
    The Biotech Selloff: It's Déjà Vu All Over Again Mar 26 2015
    The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
    Kite Pharma (KITE) Posts Wider-Than-Expected Q4 Loss - Tale of the Tape Mar 26 2015
    Trading the selloff: 8 stocks to buy Mar 25 2015
    Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
    Dismal Data Drops Dow 300 Points, Nasdaq Crumbles as Biotech Tumbles Mar 25 2015
    Biotech in nice uptrend: Adami Mar 25 2015
    Trading the selloff: 8 stocks to buy Mar 25 2015
    The Genomic Portrait of a Nation Mar 25 2015
    Worries Bubble About Biotech Mar 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK